Secretory IgA Extraction from Intestinal Fluid for Feed Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective method to produce secretory IgA with diverse antigen binding activity for use as a supplement to treat related disorders, and current methods for its production are limited, particularly for use in animals, where the diversity of antigen binding activity increases with environmental exposure.
Innovation Solution
A food composition containing pasteurized intestinal secretory IgA from pig or cow intestinal luminal fluid or mucosa, with greater than 10% of the proteinaceous material being IgA, or unhydrolyzed dried intestinal mucosa, is used to increase growth rate, improve feed efficiency, and reduce gastrointestinal inflammation and infection risk, along with a process involving polyethylene glycol precipitation and purification for isolating and purifying secretory IgA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If secretory IgA is produced using conventional methods (chemistry, recombinant microorganism fermentation, or stem cells), then production is possible, but the diversity of antigen binding activity is limited
Solution Approach 1:
The patent extracts secretory IgA directly from intestinal luminal fluid or mucosa of animals, bypassing the need for complex chemical synthesis, recombinant microorganism fermentation, or stem cell methods. This extraction approach naturally preserves the diverse antigen binding activity that develops through animal exposure to environmental antigens, while avoiding the complexity of artificial production methods.
2Adaptability or versatility
If secretory IgA is collected from animals for use as dietary/oral supplement, then diverse antigen binding activity is achieved, but the cost effectiveness is reduced
Solution Approach 1:
The patent utilizes animals that naturally produce secretory IgA in their intestinal luminal fluid as a self-service source. Rather than requiring expensive pharmaceutical-grade production methods, the approach collects IgA from the natural bodily secretions of healthy animals, making the therapy more cost-effective while maintaining diverse antigen binding activity.
Solution Approach 2:
The patent changes the concentration parameter by requiring greater than 10% of the proteinaceous material to be IgA, ensuring high potency in the collected preparation. This concentration threshold allows for effective therapeutic doses while maintaining cost-effectiveness through efficient collection and purification processes.
3Adaptability or versatility
If intestinal luminal fluid or mucosa is used as source of secretory IgA, then diverse antigen binding activity is obtained, but purification complexity increases
Solution Approach 1:
The patent extracts secretory IgA from intestinal luminal fluid or mucosa using purification processes that isolate the IgA while removing other proteins and contaminants. The requirement that greater than 10% of the proteinaceous material be IgA ensures effective purification without requiring excessively complex multi-step processes.
4Reliability
If pasteurization is applied to SIgA preparations, then effectiveness is enhanced, but processing time and energy consumption increase
Solution Approach 1:
The patent applies pasteurization parameters (temperature, time, and pH conditions) to enhance the effectiveness of SIgA preparations. By optimizing these parameters, the process achieves reliable therapeutic效果 while minimizing energy consumption and processing time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of secretory IgA in animal feed compositions effectively increases growth rate, improves feed efficiency, reduces gastrointestinal inflammation, and decreases infection risk, with pasteurization enhancing the effectiveness of the SIgA preparations.
Implementation Method 1
treating the intestinal luminal fluid of a pig with polyethylene glycol having a molecular weight of 3000 to 30,000 to precipitate the secretory IgA
Implementation Method 2
a pasteurised intestinal secretory IgA-containing intestinal luminal fluid preparation
Data Source
AI summary
Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to increase growth rate, improve feed efficiency, reduce gastrointestinal inflammation, reduce a risk of gastrointestinal infection in the animal, or a combination thereof.